NEW YORK – Burning Rock Biotech said this week that its board of directors has authorized a share repurchase plan under which the company may repurchase its Class A ordinary shares in the form of American depositary shares (ADSs) with an aggregate value of up to $10 million during a 12-month period, funding the repurchase from its existing cash balance.
The board also passed a motion to pursue an alternative listing of the company’s Class A ordinary shares on an internationally recognized stock exchange. The alternative listing is expected to offer fungibility with the ADSs currently listed on the Nasdaq.
Medtech firm Ainos said this week that the Ainos SARS-CoV-2 Antigen Rapid Self-Test has received Emergency Use Authorization from the Taiwan Food and Drug Administration. The test was codeveloped and is manufactured by Taiwan Carbon Nano Technology. San Diego-based Ainos is the exclusive master sales and marketing agent for the test kit, which is for at-home use and intended for the qualitative detection of the SARS-CoV-2 virus, including the Omicron variant, from direct nasal swab specimens. Results can be returned in as little as 15 minutes, the company said.
AI-driven healthcare firm Helio Health said this week that it has changed its name to Helio Genomics. The Irvine, California-based firm said the new name better reflects its focus on epigenetics and its commitment to advancing technology for early cancer detection and surveillance. Helio Genomics’ technology platform, Eclipse, detects methylation patterns in cell-free DNA from blood samples and uses next-generation sequencing to identify biomarkers of cancer. Its HelioLiver blood test combines cfDNA methylation patterns and serum protein markers to detect hepatocellular carcinoma.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.